May, 2024
May 2024
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Erman Akkus: 2 studies from JAMA and Thyroid Journal
Apr 16, 2024, 10:57

Erman Akkus: 2 studies from JAMA and Thyroid Journal

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

1.” Second primary breast cancer among young (≤40 yr) stage 0-III breast cancer survivors: a study of JAMA.

At median 10 years:
  • 2.2% for women who did not carry a germline pathogenic variant;
  • 8.9% for carriers of a pathogenic variant;
  • PV (pathogenic variant) carriers vs non carriers sHR (sub-hazard ratio): 5.27( 1.43-19.43).

Importance of germ line genetic testing in young women with breast cancer!”

Source: Erman Akkus/X

2. ”Pembrolizumabin addition to Dabrafenib/Trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma: a study by Thyroid Journal.

Pembrolizumab added upfront or at progression vs dabra-trame alone:

  • mOS: 17 vs 9 mo, p=0.03
  • mPFS: 11 vs 4 mo, p=0.04

If dabra-trame given as neoadjuvant (before surgery), mOS: 63 mo.”

Source: Erman Akkus/X